COMPOSICION PARA PREVENIR O TRATAR ENFERMEDADES PULMONARES QUE COMPRENDE PROTEINA 1 DE UNION DE HIALURONANO Y PROTEOGLUCANO

• Main Authors: ZHOU, Dan, PARK, Bo Kyung, YUN, So Yoon, KIM, Dae Kyong, JANG, Ji Min, PIAO, Yong Wei
• Format: Patent
• Language: Spanish
• Published: 26.10.2022
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; FOODS OR FOODSTUFFS; FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BYSUBCLASSES A23B - A23J; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OFNUTRITIVE QUALITIES, PHYSICAL TREATMENT; THEIR TREATMENT, NOT COVERED BY OTHER CLASSES; VINEGAR; WINE

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE AL MENOS UNO SELECCIONADO DEL GRUPO QUE CONSISTE EN PROTEINA HAPLN1 (PROTEINA 1 DE UNION DE HIALURONANO Y PROTEOGLUCANO), UN GEN QUE CODIFICA LA PROTEINA HAPLN1 Y UN AGENTE EFICAZ PARA POTENCIAR LA EXPRESION O ACTIVAR LAS FUNCIONES DE LA PROTEINA O DEL GEN HAPLN1 COMO PRINCIPIO ACTIVO; DONDE LA PROTEINA HAPLN1 COMPRENDE UNA SECUENCIA DE AMINOACIDOS QUE TIENE AL MENOS UN 95 % DE IDENTIDAD DE SECUENCIA CON SEQ ID NO: 1. DICHA COMPOSICION ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES PULMONARES COMO BRONQUITIS CRONICA, ASMA, ENFISEMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA (EPOC). Provided are a recombinant hyaluronan and proteoglycan link protein 1 (HAPLN1), and a composition for preventing or treating pulmonary diseases, the composition comprising at least one selected from the group consisting of HAPLN1 (hyaluronan and proteoglycan link protein 1) protein, a gene coding for the HAPLN1 protein, and an effective agent for promoting the expression or activating the functions of HAPLN1 protein or gene as an active ingredient. The recombinant HAPLN1 according to the present disclosure may have superior effects of improving alveolar damage caused by aging or elastin reduction, and thus may effectively prevent or treat pulmonary diseases, such as chronic bronchitis, asthma, emphysema, and chronic obstructive pulmonary disease.